Literature DB >> 29273891

PedsQL Neurofibromatosis Type 1 Module for children, adolescents and young adults: feasibility, reliability, and validity.

Kavitha Nutakki1, James W Varni2, Nancy L Swigonski3,4.   

Abstract

The objective of the present study was to report on the measurement properties of the Pediatric Quality of Life Inventory (PedsQL) Neurofibromatosis Type 1 Module for pediatric patients ages 5-25 from the perspectives of patients and parents. The 104-item PedsQL NF1 Module and 23-item PedsQL Generic Core Scales were completed in a multi-site national study by 323 patients and 335 parents (343 families). Patients were diagnosed with NF1 using the National Institutes of Health diagnostic criteria. In addition to a Total Scale Score, 18 unidimensional scales were derived measuring skin itch bother, skin sensations, pain, pain impact, pain management, cognitive functioning, speech, fine motor, balance, vision, perceived physical appearance, communication, worry, treatment anxiety, medicines, stomach discomfort, constipation, and diarrhea. The PedsQL NF1 Module Scales evidenced excellent feasibility, excellent reliability for the Total Scale Scores (patient self-report α = 0.98; parent proxy-report α = 0.98), and good to excellent reliability for the 18 individual scales (patient self-report α = 0.71-0.96; parent proxy-report α = 0.73-0.98). Intercorrelations with the Generic Core Scales supported construct validity. Factor analysis supported the unidimensionality of the 18 individual scales. The PedsQL NF1 Module Scales demonstrated acceptable to excellent measurement properties, and may be utilized as standardized metrics to assess NF1-specific symptoms and problems in clinical research and practice in children, adolescents, and young adults.

Entities:  

Keywords:  Health-related quality of life; Neurofibromatosis; Patient-reported outcomes; Pediatrics; PedsQL; Symptoms

Mesh:

Year:  2017        PMID: 29273891     DOI: 10.1007/s11060-017-2723-2

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  35 in total

1.  The pediatric quality of life inventory: measuring pediatric health-related quality of life from the perspective of children and their parents.

Authors:  James W Varni; Christine A Limbers
Journal:  Pediatr Clin North Am       Date:  2009-08       Impact factor: 3.278

Review 2.  Clinical manifestations and management of neurofibromatosis type 1.

Authors:  James H Tonsgard
Journal:  Semin Pediatr Neurol       Date:  2006-03       Impact factor: 1.636

3.  The intraclass correlation coefficient as a measure of reliability.

Authors:  J J Bartko
Journal:  Psychol Rep       Date:  1966-08

4.  Symptom Profiles in Patients With Irritable Bowel Syndrome or Functional Abdominal Pain Compared With Healthy Controls.

Authors:  James W Varni; Robert J Shulman; Mariella M Self; Samuel Nurko; Miguel Saps; Shehzad A Saeed; Cristiane B Bendo; Ashish S Patel; Chelsea Vaughan Dark; George M Zacur; John F Pohl
Journal:  J Pediatr Gastroenterol Nutr       Date:  2015-09       Impact factor: 2.839

5.  Pediatric Functional Constipation Gastrointestinal Symptom Profile Compared With Healthy Controls.

Authors:  James W Varni; Samuel Nurko; Robert J Shulman; Mariella M Self; Miguel Saps; Cristiane B Bendo; Chelsea Vaughan Dark; John F Pohl
Journal:  J Pediatr Gastroenterol Nutr       Date:  2015-10       Impact factor: 2.839

Review 6.  Epidemiology of neurofibromatosis type 1.

Authors:  J M Friedman
Journal:  Am J Med Genet       Date:  1999-03-26

7.  PedsQL gastrointestinal symptoms module: feasibility, reliability, and validity.

Authors:  James W Varni; Cristiane B Bendo; Jolanda Denham; Robert J Shulman; Mariella M Self; Deborah A Neigut; Samuel Nurko; Ashish S Patel; James P Franciosi; Miguel Saps; Barbara Verga; Alicia Smith; Alyson Yeckes; Nicole Heinz; Annette Langseder; Shehzad Saeed; George M Zacur; John F Pohl
Journal:  J Pediatr Gastroenterol Nutr       Date:  2014-09       Impact factor: 2.839

8.  Validation of the PedsQL Epilepsy Module: A pediatric epilepsy-specific health-related quality of life measure.

Authors:  Avani C Modi; Katherine F Junger; Constance A Mara; Tanja Kellermann; Lauren Barrett; Janelle Wagner; Grace A Mucci; Laurie Bailey; Dace Almane; Shanna M Guilfoyle; Lauryn Urso; Brooke Hater; Heather Hustzi; Gigi Smith; Bruce Herrmann; M Scott Perry; Mary Zupanc; James W Varni
Journal:  Epilepsia       Date:  2017-09-13       Impact factor: 5.864

9.  PRO development: rigorous qualitative research as the crucial foundation.

Authors:  Kathryn Eilene Lasch; Patrick Marquis; Marc Vigneux; Linda Abetz; Benoit Arnould; Martha Bayliss; Bruce Crawford; Kathleen Rosa
Journal:  Qual Life Res       Date:  2010-05-30       Impact factor: 4.147

10.  Nonrandomized comparison of neurofibromatosis type 1 and non-neurofibromatosis type 1 children who received carboplatin and vincristine for progressive low-grade glioma: A report from the Children's Oncology Group.

Authors:  Joann L Ater; Caihong Xia; Claire M Mazewski; Timothy N Booth; David R Freyer; Roger J Packer; Richard Sposto; Gilbert Vezina; Ian F Pollack
Journal:  Cancer       Date:  2016-04-08       Impact factor: 6.860

View more
  6 in total

1.  Cabozantinib for neurofibromatosis type 1-related plexiform neurofibromas: a phase 2 trial.

Authors:  Michael J Fisher; Chie-Schin Shih; Steven D Rhodes; Amy E Armstrong; Pamela L Wolters; Eva Dombi; Chi Zhang; Steven P Angus; Gary L Johnson; Roger J Packer; Jeffrey C Allen; Nicole J Ullrich; Stewart Goldman; David H Gutmann; Scott R Plotkin; Tena Rosser; Kent A Robertson; Brigitte C Widemann; Abbi E Smith; Waylan K Bessler; Yongzheng He; Su-Jung Park; Julie A Mund; Li Jiang; Khadijeh Bijangi-Vishehsaraei; Coretta Thomas Robinson; Gary R Cutter; Bruce R Korf; Jaishri O Blakeley; D Wade Clapp
Journal:  Nat Med       Date:  2021-01-13       Impact factor: 53.440

2.  Measuring Health-Related Quality of Life in Pediatric Neurology.

Authors:  Monica E Lemmon; Hanna E Huffstetler; Bryce B Reeve
Journal:  J Child Neurol       Date:  2020-06-04       Impact factor: 1.987

3.  Pain, skin sensations symptoms, and cognitive functioning predictors of health-related quality of life in pediatric patients with Neurofibromatosis Type 1.

Authors:  James W Varni; Kavitha Nutakki; Nancy L Swigonski
Journal:  Qual Life Res       Date:  2018-11-21       Impact factor: 4.147

4.  PedsQL™ Spinal Cord Injury Module: Reliability and Validity.

Authors:  Kathy Zebracki; Miriam Hwang; Lawrence C Vogel; M J Mulcahey; James W Varni
Journal:  Top Spinal Cord Inj Rehabil       Date:  2022-01-19

5.  Current Recommendations for Patient-Reported Outcome Measures Assessing Domains of Quality of Life in Neurofibromatosis Clinical Trials.

Authors:  Pamela L Wolters; Ana-Maria Vranceanu; Heather L Thompson; Staci Martin; Vanessa L Merker; Andrea Baldwin; Carolina Barnett; Kimberley S Koetsier; Cynthia M Hingtgen; Christopher J Funes; James H Tonsgard; Elizabeth K Schorry; Taryn Allen; Taylor Smith; Barbara Franklin; Stephanie Reeve
Journal:  Neurology       Date:  2021-07-06       Impact factor: 11.800

6.  The development of the PlexiQoL: A patient-reported outcome measure for adults with neurofibromatosis type 1-associated plexiform neurofibromas.

Authors:  Alice Heaney; Jeanette Wilburn; Matthew Rouse; Shannon Langmead; Jaishri O Blakeley; Susan Huson; Stephen P McKenna
Journal:  Mol Genet Genomic Med       Date:  2020-10-21       Impact factor: 2.183

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.